In this blog, Boyds’ Dr Neil Fish, Chief Business Officer, and Dr Ami Patel, Senior Director, Business Development and Product Development, explore the real-world challenges of drug development – from early-stage planning to regulatory hurdles – and provide expert insights on how to avoid the common pitfalls associated.
Navigating the path from discovery to market as a biotech start-up requires far more than scientific innovation – it demands strategic planning, operational discipline, and the ability to adapt in the face of uncertainty. Drawing on years of experience supporting emerging and established companies, the experts at Boyds highlight the most common pitfalls in drug development – and how to avoid them.
Prioritise well-structured planning
A successful drug development program starts with a product specific, well-structured, realistic, phase appropriate plan. To many developers enter the field with a compelling scientific concept but lack clarity on what success looks like or how to measure progress. Defining success early – whether in terms of regulatory milestones, clinical endpoints, or investor readiness – is essential.
The plan must go beyond reaching the clinic. It should account for product viability, scalability, and alignment with both commercial and regulatory expectations. In advanced therapies, such as cell and gene therapy, the concept of success may look different to that of traditional drug development. It may focus on demonstrating proof of concept in a small population or achieving reproducibility in manufacturing rather than solely meeting clinical endpoints.
Avoid the PhD thesis approach
Drug development is not a research project. Teams that treat it like a PhD thesis, constantly tweaking processes and data without a product development roadmap integrated with regulatory strategy, decision trees and a clear path forward, often waste valuable time and resources. Whilst scientific curiosity is a real strength, it needs to be directed by strategic goals.
Successful development teams focus on gathering the data necessary to move confidently to the next phase, rather than obsessing over perfecting every detail. Effort should be concentrated on the activities that drive a program forward toward a significant and specific milestone that ties with regulatory requirements and investor interests, not on marginal gains that have little clinical or commercial impact.
The need for flexibility and adaptability
Even the most detailed plan must allow for change. Drug development rarely proceeds exactly as expected. Scientific results may be unexpected, regulators may raise concerns, or manufacturing issues may emerge. The ability to pivot in response to these challenges can be the difference between failure and long-term success.
Flexibility requires humility, openness to feedback, and the willingness to revise strategies based on new data or expert input. Contingency planning should be built into every program, and teams must be prepared to make difficult but necessary adjustments.
Create a regulatory roadmap
A strong regulatory roadmap is essential. It provides a framework for decision-making, aligns internal teams, and significantly enhances the credibility of a program in the eyes of investors and partners.
Early and ongoing engagement with regulatory authorities such as the FDA or EMA can uncover potential issues before they become blockers. Regulatory agencies are increasingly open to early dialogue, particularly for innovative therapies, and can provide valuable guidance on development plans and study design.
Effective regulatory interactions require preparation and communications should be clear, targeted, and transparent. Attempting to obscure problems or take an adversarial approach to regulators can derail development. Building a collaborative relationship based on trust and honesty increases the likelihood of a smoother regulatory journey.
Consider the manufacturing stages
Manufacturing is often overlooked in early-stage programs, but failure to plan for scale-up can have major consequences. What works in a research lab rarely translates directly to a GMP (Good Manufacturing Practice) environment.
Designing manufacturing processes with scalability, repeatability, and compliance in mind is critical. This includes early engagement with manufacturing experts, clear documentation, and a roadmap for technology transfer to contract manufacturing organizations (CMOs).
Early-stage development does not require a perfect product. However, it does require a process that is controlled, auditable, and capable of supporting the evolution toward commercial production. Regulatory agencies expect to see that companies understand their manufacturing process and have a plan to improve it as development progresses.
Secure intellectual property
Securing intellectual property is foundational to the long-term value of any drug development program. A well-considered IP strategy can be the difference between commercial success and lost opportunity.
Patent filings should be timed strategically to maximize protection without prematurely disclosing critical data. Composition of matter patents are typically the gold standard, but other forms of IP, such as method of use or process patents, can also add value.
In some cases, particularly around manufacturing processes, trade secrets may offer more practical protection than patents. Companies should consider hybrid strategies and regularly review their IP portfolio to ensure it aligns with the evolving product and business plan.
Take a bespoke clinical approach
Cell and gene therapies bring unique challenges, particularly in clinical development. These therapies often involve novel mechanisms, delivery systems, and logistical complexities that traditional trial designs don’t accommodate.
Developers must understand the target patient population, define meaningful clinical endpoints, and plan for specialized infrastructure. Regulatory requirements may demand more extensive safety data before first-in-human trials, and the development pathway may involve new or evolving guidelines.
Engaging with clinicians, patient advocacy groups, and key opinion leaders early can help shape a clinical strategy that is both feasible and aligned with real-world needs. This engagement also supports more effective trial design and recruitment.
The table below provides insights into few product and phase specific risks and consideration during the drug development process; with each consideration and risk requiring its own detailed analysis and planning.
Development stage | Small molecule drugs | Biologics (e.g., mAbs, proteins) | Advanced therapies (cell & gene therapies) |
Target validation & early research | • Target may lack disease relevance | • Complex targets & immunogenicity concerns | • Novel/unvalidated targets |
Molecular design & preclinical risk | • Issues with potency, selectivity, PK/PD | • Complexity in characterization; Glycosylation variability; Folding & stability issues; formulation challenges | • Cell viability and potency |
Clinical development (phases I–III) | • Unpredicted toxicity | • Batch-to-batch variability; biomarker & companion diagnostics; cold chain logistics | • Dose & redosing uncertainty; Severe AEs (e.g., CRS, neurotoxicity) |
Manufacturing & regulatory | • Synthesis, instability and scalability issues | • Analytical complexity & Extensive CMC; Regulatory scrutiny on comparability and CQAs | • Manual, labor-intensive manufacturing; batch-to-batch variability |
Commercialization | • Generic competition | • Cold chain logistics | • High pricing (~$1M+) |
Final thoughts
Avoiding these pitfalls requires a proactive mindset, realistic expectations, and a willingness to invest in the right expertise. Successful programs are built on a foundation of strategic planning, clear communication, and continuous adaptation.
At Boyds, the team brings a wealth of real-world insights to help early-stage biotechs avoid costly missteps and bring new, innovative therapies to patients.
Looking for guidance on your drug development strategy?
Boyds supports companies across the full lifecycle of drug development, from regulatory strategy to clinical design and scale-up. Contact us to learn how we can help you overcome common pitfalls and accelerate your path to success.